CL2012001055A1 - Dominio variable de inmunoglobina anti-tnfr1 (receptor tnf alfa tipo 1 o p55) que comprende secuencia aminoacidica al menos un 95% identica a las secuencias de dom1h-574-188, ... y dom1h-574-214; acido nucleico, vector y celula huesped que lo codifican; ligando multiespecifico; antagonista de tnfr1 y su uso antiinflamatorio. - Google Patents

Dominio variable de inmunoglobina anti-tnfr1 (receptor tnf alfa tipo 1 o p55) que comprende secuencia aminoacidica al menos un 95% identica a las secuencias de dom1h-574-188, ... y dom1h-574-214; acido nucleico, vector y celula huesped que lo codifican; ligando multiespecifico; antagonista de tnfr1 y su uso antiinflamatorio.

Info

Publication number
CL2012001055A1
CL2012001055A1 CL2012001055A CL2012001055A CL2012001055A1 CL 2012001055 A1 CL2012001055 A1 CL 2012001055A1 CL 2012001055 A CL2012001055 A CL 2012001055A CL 2012001055 A CL2012001055 A CL 2012001055A CL 2012001055 A1 CL2012001055 A1 CL 2012001055A1
Authority
CL
Chile
Prior art keywords
dom1h
tnfr1
encode
sequences
vector
Prior art date
Application number
CL2012001055A
Other languages
English (en)
Inventor
Silva Inusha De
Armin Sepp
Adriaan Allart Stoop
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43382391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001055(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CL2012001055A1 publication Critical patent/CL2012001055A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Dominio variable de inmunoglobina anti-TNFR1 (receptor TNF alfa tipo 1 o P55) que comprende secuencia aminoacídica al menos un 95% identica a las secuencias de DOM1H-574-188, ... y DOM1H-574-214; ácido nucleico, vector y célula huésped que lo codifican; ligando multiespecífico; antagonista de TNFR1 y su uso antiinflamatorio.
CL2012001055A 2009-10-27 2012-04-25 Dominio variable de inmunoglobina anti-tnfr1 (receptor tnf alfa tipo 1 o p55) que comprende secuencia aminoacidica al menos un 95% identica a las secuencias de dom1h-574-188, ... y dom1h-574-214; acido nucleico, vector y celula huesped que lo codifican; ligando multiespecifico; antagonista de tnfr1 y su uso antiinflamatorio. CL2012001055A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25523509P 2009-10-27 2009-10-27

Publications (1)

Publication Number Publication Date
CL2012001055A1 true CL2012001055A1 (es) 2012-10-05

Family

ID=43382391

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001055A CL2012001055A1 (es) 2009-10-27 2012-04-25 Dominio variable de inmunoglobina anti-tnfr1 (receptor tnf alfa tipo 1 o p55) que comprende secuencia aminoacidica al menos un 95% identica a las secuencias de dom1h-574-188, ... y dom1h-574-214; acido nucleico, vector y celula huesped que lo codifican; ligando multiespecifico; antagonista de tnfr1 y su uso antiinflamatorio.

Country Status (26)

Country Link
US (1) US20150210767A1 (es)
EP (1) EP2493504B1 (es)
JP (1) JP2013507978A (es)
KR (1) KR20120101417A (es)
CN (1) CN102686239B (es)
AR (1) AR078763A1 (es)
AU (1) AU2010311640B2 (es)
BR (1) BR112012010114A2 (es)
CA (1) CA2777312A1 (es)
CL (1) CL2012001055A1 (es)
CO (1) CO6612254A2 (es)
CR (1) CR20120197A (es)
DO (1) DOP2012000113A (es)
EA (1) EA022898B1 (es)
ES (1) ES2552177T3 (es)
IL (1) IL218860A0 (es)
MA (1) MA33758B1 (es)
MX (1) MX2012005024A (es)
NZ (1) NZ599114A (es)
PE (1) PE20121564A1 (es)
SG (1) SG10201500274TA (es)
TW (1) TW201125877A (es)
UA (1) UA107200C2 (es)
UY (1) UY32969A (es)
WO (1) WO2011051217A1 (es)
ZA (1) ZA201203052B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG173173A1 (en) * 2009-02-19 2011-08-29 Glaxo Group Ltd Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
EP2721066A1 (en) * 2011-06-17 2014-04-23 Glaxo Group Limited Tumour necrosis factor receptor 1 antagonists
US20150368292A1 (en) * 2013-01-31 2015-12-24 Glaxo Group Limited Method of producing a protein
WO2015104322A1 (en) 2014-01-09 2015-07-16 Glaxosmithkline Intellectual Property Development Limited Treatment of inflammatory diseases with non-competitive tnfr1 antagonists
SG11201808680RA (en) * 2016-04-05 2018-11-29 Univ Stuttgart MONOVALENT INHIBITOR OF huTNFR1 INTERACTION
EP4204094A1 (en) 2020-08-27 2023-07-05 Enosi Therapeutics Corporation Methods and compositions to treat autoimmune diseases and cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
CN114699533B (zh) * 2022-05-06 2023-05-09 郑州大学 一种核酸适配体和多肽交联的双靶点复合核酸纳米药物制备方法与应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
PT1801214E (pt) 1997-07-07 2011-01-20 Medical Res Council Método de triagem in vitro
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
CA2399388A1 (en) 2000-02-11 2001-08-16 Michael J. Lenardo Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
JP2006523090A (ja) 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
US20090005257A1 (en) 2003-05-14 2009-01-01 Jespers Laurent S Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
SI1729795T1 (sl) 2004-02-09 2016-04-29 Human Genome Sciences, Inc. Albuminski fuzijski proteini
CN101084014A (zh) * 2004-10-08 2007-12-05 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
KR20100018040A (ko) 2007-06-06 2010-02-16 도만티스 리미티드 프로테아제 내성 폴리펩티드를 선택하는 방법
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
SG173173A1 (en) * 2009-02-19 2011-08-29 Glaxo Group Ltd Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
EP3330287B1 (en) * 2009-02-19 2019-12-18 Glaxo Group Limited Improved anti-serum albumin binding variants

Also Published As

Publication number Publication date
IL218860A0 (en) 2012-06-28
CR20120197A (es) 2012-06-22
EA022898B1 (ru) 2016-03-31
NZ599114A (en) 2014-09-26
US20150210767A1 (en) 2015-07-30
ES2552177T3 (es) 2015-11-26
CN102686239B (zh) 2016-02-03
AU2010311640B2 (en) 2015-01-29
EP2493504A1 (en) 2012-09-05
PE20121564A1 (es) 2012-11-29
SG10201500274TA (en) 2015-03-30
DOP2012000113A (es) 2012-08-15
KR20120101417A (ko) 2012-09-13
CN102686239A (zh) 2012-09-19
MX2012005024A (es) 2012-09-07
WO2011051217A1 (en) 2011-05-05
CO6612254A2 (es) 2013-02-01
BR112012010114A2 (pt) 2017-08-08
CA2777312A1 (en) 2011-05-05
TW201125877A (en) 2011-08-01
AR078763A1 (es) 2011-11-30
EP2493504B1 (en) 2015-10-07
AU2010311640A1 (en) 2012-05-10
JP2013507978A (ja) 2013-03-07
EA201290172A1 (ru) 2013-04-30
UY32969A (es) 2011-05-31
UA107200C2 (uk) 2014-12-10
MA33758B1 (fr) 2012-11-01
ZA201203052B (en) 2013-09-25

Similar Documents

Publication Publication Date Title
CL2012001055A1 (es) Dominio variable de inmunoglobina anti-tnfr1 (receptor tnf alfa tipo 1 o p55) que comprende secuencia aminoacidica al menos un 95% identica a las secuencias de dom1h-574-188, ... y dom1h-574-214; acido nucleico, vector y celula huesped que lo codifican; ligando multiespecifico; antagonista de tnfr1 y su uso antiinflamatorio.
CL2008001673A1 (es) Dominio variable simple de la inmunoglobulina del receptor tipo 1 de la anti-interleucina 1 (il-1r1); acido nucleico que lo codifica; vector y celula huesped; metodo de produccion; antagonista de il-1r1 que lo comprende; composicion que comprende al antagonista; y uso del antagonista para tratar una condicion inflamatoria.
AR069681A1 (es) Moleculas de union al receptor ox40 humano
Angelopoulos et al. Does public sector efficiency matter? Revisiting the relation between fiscal size and economic growth in a world sample
CL2011002660A1 (es) Anticuerpo anti-receptor de activinas tipo iib (anti-actr-iib); secuencia de polinucleotidos aislados que codifica dicho anticuerpo; vector, celula huesped; composicion farmaceutica; uso para tratar transtornos musculo esqueleticos.
CL2010001543A1 (es) Inmunoenlazador que se une especificamente al factor de necrosis tumoral alfa (tnf alfa); que comprende los cdr de conejo y las secuencias marco humanas; acido nucleico que lo codifica; celula huesped; composicion que lo comprende; y su uso para tratar o prevenir una enfermedad mediada por tnf alfa.
EP4303314A3 (en) Polypeptide tagged nucleotides and use thereof in nucleic acid sequencing by nanopore detection
EP4071176A3 (en) Agonistic tnf receptor binding agents
CL2017002514A1 (es) Anticuerpos anti-c1s humanizados y métodos para usarlos.
EP4257596A3 (en) Coumarin compounds and their uses as fluorescent labels
BR112014006390A2 (pt) anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano
BR112012015740A2 (pt) anticorpos de anti-flt3 e metodos de uso dos mesmos
CL2011001296A1 (es) Anticuerpo monoclonal capaz de inhibir la dimerizacion de cmet; acido nucleico, vector y celula huesped que comprenden las secuencias que codifican el anticuerpo; composicion que comprende el anticuerpo; uso del anticuerpo para inhibir el crecimiento y/o proliferacion de celulas tumorales.
NZ740630A (en) Polymethine compounds and their use as fluorescent labels
CL2011002768A1 (es) Polipéptido mutante fgf21; ácido nucleico que lo codifica; vector; célula huésped; composición farmacéutica que lo comprende; y su uso para tratar un trastorno metabólico.
AR090909A1 (es) Antagonistas de st2l y metodos de uso
BR112018004965A2 (pt) domínios de superfamìlia de imunoglobulina variante ajustàvel
EA201400811A1 (ru) Двойная индуцированная антигеном двухкомпонентная функциональная комплементация
MX337040B (es) Moleculas de union a 4-1bb.
CL2009000459A1 (es) Anticuerpo se une a la proteina rgm a; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; construccion de anticuerpos que comprende dicha proteina; conjugado de anticuerpos que comprende a la construccion; uso.
CL2013000369A1 (es) Anticuerpo que se une especificamente a la proteina de activacion fibroblastica (fap); polinucleotido que lo codifica; vector; celula huesped; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar cancer.
CR20110245A (es) Mutantes fgf21 y uso de los mismos.
CL2013001213A1 (es) Anticuerpo para interleuquina 17 (il-17); uso de este para tratar artritis reumatoide.
CL2011000730A1 (es) Procedimiento de selección de anticuerpos anti-cxcr4 y anticuerpos seleccionados; ácido nucleico que codifica los anticuerpos; vector; célula huésped; procedimiento de producción; hibridoma que produce los anticuerpos; composición; uso de los anticuerpos seleccionados para preparar un medicamento para tratar cáncer.
BRPI1007005A2 (pt) anticorpo isolado , ácido nucleico isolado n vetor, célula isolada , linhagem de célula isolada , composição farmacêutica, e, uso de um anticorpo anti-il-6